Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04473690 · ClinicalTrials.gov registry record · Phase 1

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

A Phase 1 study of COVID-19, sponsored by KBio.

Completed
Registry status
Phase 1
Development phase
102
Enrollment target
8
Study locations

NCT04473690: Completed Phase 1 study of COVID-19, sponsored by KBio.

NCT04473690 is a Phase 1 study of COVID-19 that has completed, run by KBio. The registered enrollment target is 102 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04473690, a Phase 1 study of COVID-19, has completed, sponsored by KBio.

COMPLETED
Registry status
Phase 1
Development phase
102 participants
Enrollment target
8
Study locations

Study Summary

This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-85 years).

Primary Outcome

Occurrence of Adverse Events

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Low Dose of KBP-COVID-19
  • BIOLOGICAL High Dose of KBP-COVID-19

Study Locations (8)

Texas

  • PanAmerican Clinical Research - Brownsville
  • ICON - San Antonio
  • DM Clinical Research - Tomball

Florida

  • Palm Beach Research Center - West Palm Beach

Idaho

  • Velocity Clinical Research - Meridian

North Carolina

  • PMG Research of Winston-Salem - Winston-Salem

Burlington/Ontario

  • LMC Manna Research - Burlington

Point Claire, Quebec

  • LMC Manna Research - Montreal

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2020-12-30
Est. Completion 2022-10-14
Phase Phase 1
KBio

4 total trials

What the finished NCT04473690 record still lists

NCT04473690 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04473690 lists 8 locations in 6 states (Texas, Florida, Idaho).

Frequently Asked Questions

What is clinical trial NCT04473690 about?

NCT04473690 is a clinical study titled "KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers". This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-85 years).

What is the current status of trial NCT04473690?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2020-12-30. Estimated completion is 2022-10-14.

What conditions does trial NCT04473690 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT04473690?

The interventions under investigation include: Placebo (BIOLOGICAL), Low Dose of KBP-COVID-19 (BIOLOGICAL), High Dose of KBP-COVID-19 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04473690?

This trial is sponsored by KBio, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04473690 being conducted?

This trial has 8 study locations across Florida, Idaho, North Carolina, Texas, Burlington/Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04473690's enrollment target sits among peer trials

102 199th of 298 higher than 100 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04473690, the US trial registry maintained by the National Library of Medicine. NCT04473690 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.